#United States #Boston #IL-22 #Ampersand Biomedicines #AMP-220

Ampersand Biomedicines Presents Innovative Preclinical Data on AMP-220

In recent developments at AAI 2026, held from April 15 to 19, Ampersand Biomedicines, a pioneering multi-product platform company, revealed promising preclinical data for their novel gut-targeted therapeutic, AMP-220. This innovative treatment focuses on the IL-22 AND-Body™, demonstrating targeted efficacy specifically in gut tissue, which is pivotal for patients suffering from inflammatory bowel disease (IBD).

The Need for Precision in IBD Treatments

Inflammatory bowel disease, including conditions such as Crohn’s disease and ulcerative colitis, has long been a challenge in the medical field due to the systemic side effects related to current therapies. Traditional IL-22 therapies often suffer from dose-limiting toxicities due to their non-specific action, causing adverse reactions in non-target areas like the skin. The introduction of AMP-220 aims to address these issues by selectively delivering therapeutic benefits precisely to the gut.

Dr. Daniël Blom, Chief Scientific Officer of Ampersand Biomedicines, elucidated on the challenges and potential of using IL-22 in therapeutic applications. According to him, while IL-22 is promising for restoring barrier function in the gut, its broader use has been hampered by its adverse off-target effects. AMP-220 seeks to change this by ensuring that IL-22 activity is focused on gut tissue, thereby enhancing therapeutic outcomes while minimizing harmful side effects.

Key Findings from Preclinical Data

During the oral presentation, Ampersand showcased various in vitro and in vivo studies highlighting the following key findings:

• - Selective Action: AMP-220 effectively activates IL-22 specifically within the gut epithelium, substantiating its role in providing therapeutic effects for IBD while showing negligible toxicity in other tissues.
• - Enhanced Potency: The research found AMP-220 exhibited a 2,000-fold increase in potency compared to non-targeted IL-22 therapies, showcasing its superior efficacy in human intestinal epithelial cells.
• - Disease Mitigation: In mouse models of colitis, AMP-220 significantly reduced weight loss associated with the condition and demonstrated potential for disease resolution.
• - Improved Therapeutic Index: Tests in non-human primates showed that an analog of AMP-220 had increased activity in the colon and reduced systemic effects, confirming a better therapeutic profile compared to conventional IL-22 treatments.

The Future of AMP-220 and AND-Body™ Technology

Jason Gardner, CEO of Ampersand Biomedicines, expressed excitement about the promising results presented, reinforcing the capabilities of their AND-Body™ approach. This groundbreaking method combines a localizing antibody with an optimized actuator designed to target therapies effectively where needed. The precision of this approach could revolutionize treatment options for numerous diseases beyond IBD.

As Ampersand Biomedicines gears up for advanced IND-enabling studies, there is great anticipation regarding the potential for AMP-220 to transition into clinical trials next year, potentially paving the way for a new wave of more effective, tailored therapies for patients.

Ampersand Biomedicines: A Commitment to Precision Medicine

Founded by Flagship Labs in 2021, Ampersand Biomedicines is committed to redefining how medicines are developed to achieve the greatest impact at the site of disease. By leveraging their innovative AND™ Platform, they aim to create safe and effective therapeutics that minimize systemic risks while maximizing local therapeutic effects. For more details on their groundbreaking work and advancements in precision medicine, visit Ampersand Biomedicines or follow them on LinkedIn.